☆ 4.7 Letter

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Related references

Note: Only part of the references are listed.
Letter Oncology

COVID-19 and myeloproliferative neoplasms: some considerations

Baransel Kamaz et al.

LEUKEMIA (2021)

Add to Collection
Article Oncology

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui et al.

Summary: The study found a high risk of mortality among MPN patients during COVID-19 infection, especially in MF patients and those discontinuing Ruxo treatment. Further investigation is needed on the role of Ruxo treatment and its interruption in affecting mortality in MPN patients with COVID-19.

LEUKEMIA (2021)

Add to Collection
Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

Lorenzo Iovino et al.

Summary: COVID-19 and IMTX-related toxicities share potential common mechanisms and differences, with anti-inflammatory therapy potentially reducing mortality in COVID-19 by targeting cytokines involved in its pathogenesis, particularly by inhibiting the interleukin-6 pathway. Other approaches based on novel drugs and cell therapies are currently under investigation and may lead to a reduction in hospitalization and mortality due to COVID-19.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Letter Oncology

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington et al.

LEUKEMIA (2021)

Add to Collection
Review Public, Environmental & Occupational Health

The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis

Indra Wijaya et al.

Summary: The use of JAK inhibitors was found to be significantly associated with reduced risk of mortality and clinical improvement in hospitalized patients with COVID-19, but not with clinical deterioration.

CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH (2021)

Add to Collection
Article Microbiology

Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively

Fabrizio Bonelli et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.